---
title: "Alvotech (ALVO) news: offering"
url: "https://aibio.space/companies/alvotech/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ALVO offering news: Alvotech launches $125 million share sale, then prices 22,666,667 shares at $3.750. Alvotech (NASDAQ: ALVO), Luxembourg."
---

ALVO Alvotech NASDAQ · Luxembourg

# Alvotech (ALVO) news ALVO offering news

Debt Financing · 2026-07-01

## [Alvotech secures $75 million term loan from GoldenTree funds](https://aibio.space/news/alvotech-secures-75-million-term-loan-goldentree-funds/)

Alvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025.

## Latest Alvotech news

1. 2026-06-15 Financings [Alvotech launches $125 million share sale, then prices 22,666,667 shares at $3.750](https://aibio.space/news/alvotech-launches-125-million-share-sale-then-prices-22-666-667-shares/) Alvotech priced 22,666,667 shares at $3.750, below its $4.24 Nasdaq close on June 15, and a private placement of 17,826,666 shares to European investors is set to add about $66.85 million.

## Alvotech at a glance

- **Ticker**: ALVO

- **Listing**: NASDAQ

- **Country**: Luxembourg

### Related companies

- [Procaps Group](https://aibio.space/companies/procaps-s-a/) OTC: PROCF

### Also on NASDAQ

- [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) IAM
- [Milestone Pharmaceuticals](https://aibio.space/companies/milestone-pharmaceuticals/) MIST
- [Pulmonx](https://aibio.space/companies/pulmonx/) LUNG
- [20/20 Biolabs](https://aibio.space/companies/20-20-biolabs/) AIDX
- [Fulgent Genetics](https://aibio.space/companies/fulgent-genetics/) FLGT
- [Caris Life Sciences](https://aibio.space/companies/caris-life-sciences/) CAI

## What Alvotech does

Alvotech is a vertically integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines. It was founded in 2013 in Reykjavik, Iceland, and conducts its business through its wholly owned subsidiary, Alvotech hf. The company says it has invested over $2 billion to build a platform for developing and manufacturing biosimilars at scale. It licenses its biosimilars intellectual property to commercialization partners in exchange for development and commercialization milestone payments and royalties on sales. It has five approved products and thirty product candidates in its pipeline, targeting autoimmune, eye, respiratory and hematological diseases, as well as cancer. Its approved biosimilars include AVT02, a biosimilar to Humira (adalimumab), AVT04, a biosimilar to Stelara (ustekinumab), AVT05, a biosimilar to Simponi (golimumab), and AVT06, a biosimilar to Eylea (aflibercept). Its stated mission is broadening the availability and accessibility of biosimilars, and it says its platform may allow expansion into other healthcare product areas such as respiratory and primary care products.

| Product or program | What it is | Stage |
|---|---|---|
| AVT02 | Biosimilar to Humira (adalimumab) | approved in various major markets, including the U.S. |
| AVT04 | Biosimilar to Stelara (ustekinumab) | approved in various major markets, including the U.S. and Japan |
| AVT05 | Biosimilar to Simponi (golimumab) | approved for marketing in the UK, European Economic Area and Japan |
| AVT06 | Biosimilar to Eylea (aflibercept) | approved for marketing in the UK, European Economic Area and Japan |

Summarised from the company's [20-F filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm).

## Questions about Alvotech

Has Alvotech raised money recently?

Our latest story on this, dated Jun 15, 2026: "Alvotech launches $125 million share sale, then prices 22,666,667 shares at $3.750". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alvotech-launches-125-million-share-sale-then-prices-22-666-667-shares/).

What is the ticker symbol of Alvotech?

Alvotech trades under the ticker ALVO on NASDAQ.

Where is Alvotech listed?

Alvotech is listed on NASDAQ. Our directory also records these other listings: GETTEX:Z45; LS:A3DK8U; LSX:A3DK8U; OMXICE:ALVO; OMXSTO:ALVO_SDB.

What is the SEC CIK of Alvotech?

The SEC Central Index Key (CIK) for Alvotech is 1898416. Its filings are on SEC EDGAR.

How many shares does Alvotech have outstanding?

312,021,375 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31.

Which country or territory is Alvotech listed under?

Our directory records Alvotech under Luxembourg.

What does Alvotech do?

Our directory classifies Alvotech as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Alvotech?

The ISIN recorded for Alvotech is LU2458332611.

Does aibio.space cover Alvotech?

aibio.space lists Alvotech among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Alvotech incorporated?

SEC records list its state or country of incorporation as N4.

What does Alvotech develop?

Alvotech is a vertically integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines. It was founded in 2013 in Reykjavik, Iceland, and conducts its business through its wholly owned subsidiary, Alvotech hf.

What is AVT02 from Alvotech?

AVT02: Biosimilar to Humira (adalimumab) Stage: approved in various major markets, including the U.S..

What is AVT04 from Alvotech?

AVT04: Biosimilar to Stelara (ustekinumab) Stage: approved in various major markets, including the U.S. and Japan.

What is the latest Alvotech (ALVO) stock news?

Our latest story on Alvotech, dated Jul 1, 2026: "Alvotech secures $75 million term loan from GoldenTree funds". Alvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025. [Source](https://aibio.space/news/alvotech-secures-75-million-term-loan-goldentree-funds/).

Does Alvotech have debt, a term loan or convertible notes?

Our latest debt story, dated Jul 1, 2026: "Alvotech secures $75 million term loan from GoldenTree funds". Alvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025. [Source](https://aibio.space/news/alvotech-secures-75-million-term-loan-goldentree-funds/).

## Investor discussion: Alvotech

Members talk about Alvotech (ALVO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Alvotech, newest first. Each line links the filing it comes from.

1. 2026-06-15 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1898416/000093041326001857/c116682_424b5.htm)
2. 2025-12-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1898416/000117184325007974/exh_991.htm)
3. 2025-06-12 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1898416/000117184325003869/exh_991.htm)
4. 2025-05-27 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_991.htm)
5. 2024-11-13 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1898416/000117184324006347/exh_991.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALVO on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALVO/).

## SEC filings and registration

- **SEC name**: Alvotech

- **CIK**: 1898416

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: ALVO (Nasdaq), ALVOW (Nasdaq)

- **State or country of incorporation**: N4

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 9, RUE DE BITBOURG, LUXEMBOURG, Luxembourg, L-1273

- **Phone**: 354 422-4500

- **Shares outstanding**: 312,021,375 as of 2025-12-31 (20-F filed 2026-03-31)

- **Former names**: Alvotech Lux Holdings S.A.S.

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006704/f6k_102026.htm) filed 2026-10-20
- [6-K](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006617/f6k_101426.htm) filed 2026-10-14
- [6-K](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006489/f6k_100726.htm) filed 2026-10-07
- [6-K](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006383/f6k_100526.htm) filed 2026-10-05
- [6-K](https://www.sec.gov/Archives/edgar/data/1898416/000117184326005793/f6k_083126.htm) filed 2026-08-31
- [6-K](https://www.sec.gov/Archives/edgar/data/1898416/000117184326005697/f6k_082126.htm) filed 2026-08-21
- [6-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828026057988/alvo-20260630_d2.htm) filed 2026-08-19
- [6-K](https://www.sec.gov/Archives/edgar/data/1898416/000117184326004991/f6k_072926.htm) filed 2026-07-29

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001898416), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Alvotech is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ALVO, recorded under Luxembourg. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Alvotech

- **Ticker**: ALVO

- **Listing**: NASDAQ

- **Country or territory**: Luxembourg

- **Business scope**: Biotechnology

- **ISIN**: LU2458332611

- **Other listed symbols**: GETTEX:Z45; LS:A3DK8U; LSX:A3DK8U; OMXICE:ALVO; OMXSTO:ALVO_SDB

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ALVO/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/alvotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alvotech (ALVO) news: offering", 2026-10-31, https://aibio.space/companies/alvotech/